MetLife Investment Advisors »

Sab Biotherapeutics shares owned by MetLife Investment Advisors

Quarter-by-quarter ownership of Sab Biotherapeutics (SABS) shares owned by MetLife Investment Advisors from 13F filings

Historical chart of MetLife Investment Advisors investment in Sab Biotherapeutics

Tip: Access up to 7 years of quarterly data

All positions including Sab Biotherapeutics held by MetLife Investment Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Sab Biotherapeutics by MetLife Investment Advisors

Quarter filed Position value Share count Share price at filing
2026-06-30 $109k 28k 3.90

More positions owned by MetLife Investment Advisors

NVIDIA Corporation (NVDA)
Apple (AAPL)
Microsoft Corporation (MSFT)
Alphabet Inc Class A Cap Stk Cl A (GOOGL)
Amazon (AMZN)
Broadcom (AVGO)
Alphabet Inc Class C Cap Stk Cl C (GOOG)
Micron Technology (MU)
Meta Platforms Inc Class A Cl A (META)
Tesla Motors (TSLA)
Eli Lilly & Co. (LLY)
Advanced Micro Devices (AMD)
Berkshire Hathaway Inc Class B Cl B New (BRK.B)
JPMorgan Chase & Co. (JPM)
Vanguard Short-term Bond Index Fun Short Trm Bond (BSV)

View all positions for MetLife Investment Advisors

Top funds holding Sab Biotherapeutics

Caligan Partners
Vivo Capital
Perceptive Advisors
Adage Capital Partners GP
RA Capital Management
Balyasny Asset Management
BlackRock
Vanguard Capital Management
Commodore Capital
Millennium Management
Spruce Street Capital
Sessa Capital IM
Affinity Asset Advisors
Boothbay Fund Management
Geode Capital Management

View all funds holding Sab Biotherapeutics